AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review 2020-present
{{output}}
Introduction: Aldo-keto reductase 1C3 (AKR1C3) is a drug target for the treatment of various androgen dependent malignancies, including castration-resistant prostate canceras well as hematological cancers. The enzyme plays a key ... ...
